ArticleCancer management and research2026
LONP2 Enhances Cervical Cancer Growth and Metastatic Potential by Upregulating PLS3 and Activating PI3K/AKT Signaling.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to investigate the role of LONP2 in cervical cancer progression and elucidate the underlying signaling mechanisms. Methods: HeLa cervical cancer cells were transduced with lentiviral vectors to overexpress LONP2 or simultaneously overexpress LONP2 and knock down plastin 3 (PLS3). Protein expression was assessed by Western blotting. Cell viability, apoptosis, migration, and invasion were evaluated using CCK-8 assays, flow cytometry, and Transwell assays, respectively. The involvement of the PI3K/AKT signaling pathway was examined by detecting the phosphorylation levels of PI3K and AKT. A nude mouse xenograft model was established to validate the in vitro findings. Results: LONP2 overexpression significantly increased PLS3 protein expression in cervical cancer cells. Functionally, LONP2 promoted cell proliferation, migration, invasion, and tumor growth while suppressing apoptosis. Knockdown of PLS3 markedly attenuated these tumor-promoting effects both in vitro and in vivo. Mechanistically, LONP2 overexpression enhanced the phosphorylation of PI3K and AKT without significantly affecting total PI3K or AKT expression, indicating activation of the PI3K/AKT signaling pathway. Importantly, silencing PLS3 effectively reversed LONP2-induced PI3K/AKT pathway activation. Consistent findings were observed in xenograft tumors, where PLS3 knockdown suppressed tumor growth and reduced p-PI3K and p-AKT expression. Conclusion: LONP2 promotes cervical cancer progression by upregulating PLS3 expression and activating the PI3K/AKT signaling pathway. The LONP2/PLS3/PI3K-AKT signaling axis represents a novel mechanism driving cervical cancer progression and may serve as a potential therapeutic target for cervical cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.